Alternative asset management firm TPG (NASDAQ: TPG) declared on Monday that it has made a strategic investment in K2 Medical Research, an integrated clinical trial site platform specialising in central nervous system trials.
Founded by CEO Sean Stanton and CMO Brandon Lenox, K2 operates clinical trial sites across Florida, focusing on complex therapeutic areas such as Alzheimer's and psychiatry. With a robust track record of over 150 studies for leading pharma sponsors, including AbbVie and Johnson & Johnson, K2 is known for its strong site operators and community-focused approach.
The partnership aims to enhance K2's capabilities in patient recruitment, utilising a diverse staffing model, and deploying a mobile research unit (Wanda) to engage local communities directly. K2's agile start-up process and fully integrated technology platform streamline clinical trial management from initiation to completion, reinforcing its leadership in clinical research.
Financial terms of the investment were not disclosed.
Foley & Lardner LLP advised K2, while Latham & Watkins LLP represented TPG, with Harris Williams serving as financial advisor to TPG.
Lipocine doses first cohort in LPCN 1154 study
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials